<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351321</url>
  </required_header>
  <id_info>
    <org_study_id>CLASS08</org_study_id>
    <nct_id>NCT04351321</nct_id>
  </id_info>
  <brief_title>The Safety of Totally Laparoscopic Versus Laparoscopy-Assisted Total Gastrectomy.</brief_title>
  <official_title>A Multicenter, Randomized, Controlled Clinical Trial of the Safety of Totally Laparoscopic Versus Laparoscopy-Assisted Total Gastrectomy for Gastric Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the short-term surgical safety and postoperative quality of life of totally&#xD;
      laparoscopic versus laparoscopy-assisted total gastrectomy and to evaluate the superiority of&#xD;
      totally laparoscopic total gastrectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of postoperative morbidity</measure>
    <time_frame>30 days</time_frame>
    <description>Refers to the incidence of early postoperative complications. The early postoperative complications are defined as the events observed within postoperative 30 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Quality of life scores of the patients are evaluated based on EORTC C30 questionnaire at the 3rd, 6th and 12th months after operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Quality of life scores of the patients are evaluated based on STO22 questionnaire at the 3rd, 6th and 12th months after operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall incidence of postoperative morbidity</measure>
    <time_frame>12 months</time_frame>
    <description>Refers to the incidence of overall postoperative complications observed during follow-up period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">560</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Totally Laparoscopic Total Gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Totally laparoscopic total gastrectomy will be performed for the treatment of patients assigned to this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopy-Assisted Total Gastrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laparoscopy-assisted total gastrectomy will be performed for the treatment of patients assigned to this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Totally Laparoscopic Total Gastrectomy</intervention_name>
    <description>Totally laparoscopic total gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.</description>
    <arm_group_label>Totally Laparoscopic Total Gastrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopy-Assisted Total Gastrectomy</intervention_name>
    <description>Laparoscopy-Assisted Total Gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.</description>
    <arm_group_label>Laparoscopy-Assisted Total Gastrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18-75 years；&#xD;
&#xD;
          2. Primary lesion is diagnosed with endometrial biopsy as adenocarcinoma of the stomach&#xD;
             or esophagogastric junction, including: papillary adenocarcinoma, tubular&#xD;
             adenocarcinoma, mucinous adenocarcinoma, poorly cohesive carcinoma (including signet&#xD;
             ring cell carcinoma and other variants), mixed adenocarcinoma, etc.；&#xD;
&#xD;
          3. Clinical stage cT1N0M0, cT1N1M0, cT2N0M0；&#xD;
&#xD;
          4. The gastric primary lesion is located in the body or fundus of stomach or the&#xD;
             esophagogastric junction. It is expected that total gastrectomy with D1+/D2 lymph node&#xD;
             dissection achieves R0 resection (multiple primary cancers are also applicable)；&#xD;
&#xD;
          5. BMI(Body Mass Index)&lt;30 kg/m2；&#xD;
&#xD;
          6. No history of upper abdominal surgery (except for laparoscopic cholecystectomy)；&#xD;
&#xD;
          7. No prior treatment of chemotherapy, radiotherapy, targeted therapy, immunotherapy,&#xD;
             etc.；&#xD;
&#xD;
          8. Preoperative ECOG (Eastern Cooperative Oncology Group) performance status score 0 or&#xD;
             1；&#xD;
&#xD;
          9. Preoperative ASA (American Society of Anesthesiologists) scoring I-III；&#xD;
&#xD;
         10. Sufficient vital organ functions；&#xD;
&#xD;
         11. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Preoperative examination indicates disease stage cStage II or above；&#xD;
&#xD;
          2. Women during pregnancy or lactation；&#xD;
&#xD;
          3. Suffer from other malignant tumors within 5 years；&#xD;
&#xD;
          4. Preoperative body temperature ≥ 38°C or complicated with infectious diseases requiring&#xD;
             systemic treatment；&#xD;
&#xD;
          5. Severe mental illness；&#xD;
&#xD;
          6. Severe respiratory disease；&#xD;
&#xD;
          7. Severe liver and kidney dysfunction；&#xD;
&#xD;
          8. History of unstable angina or myocardial infarction within 6 months；&#xD;
&#xD;
          9. History of cerebral infarction or cerebral hemorrhage within 6 months；&#xD;
&#xD;
         10. Continuous application of glucocorticoid within 1 month (except for topical&#xD;
             application)；&#xD;
&#xD;
         11. Accompanied by gastric cancer complications (bleeding, perforation, obstruction, etc.)&#xD;
             ；&#xD;
&#xD;
         12. The patient has participated in or is participating in other clinical studies (within&#xD;
             6 months).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zekuan Xu, M.D., Ph.D.</last_name>
    <phone>+86-025-68306844</phone>
    <email>xuzekuan@njmu.edu.cn</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

